skip to main |
skip to sidebar
Array BioPharma and AstraZeneca : New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
May 15, 2008 - Array BioPharma Inc. (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half of 2008, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244's activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies.
The data from these earlier clinical trials will be presented at the forthcoming American Society of Clinical Oncology Annual Meeting... Array BioPharma's Press Release -
May 15, 2008 - Array BioPharma Inc. (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half of 2008, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244's activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies.
